The African Kelleni’s roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one

Abstract

For over 3.5 years, SARS CoV-2 is continuing to evolve threatening to return all and any improvement the world has made into square one. In this clinically oriented systematic review and perspective, the author explains how the best current medical evidence is strongly supporting the use of the low cost, widely available and very safe nitazoxanide in early management of COVID-19, debates the relevant theoretical studies that negated or doubted this benefit, and suggests an African roadmap to preempt the worst-case scenario if or when a new SARS CoV-2 (sub) variant or even a new respiratory virus causes a new global surge of morbidity and mortality. Kelleni’s protocol, including nitazoxanide as an integral component, is continuing to perfectly save lives of patients infected with many viruses, including SARS CoV-2 and the author stresses that respiratory RNA viruses are best managed with early pharmacological treatment. Broad-spectrum antimicrobials as nitazoxanide and azithromycin together with other therapeutics as non-steroidal anti-inflammatory drugs and the antihistaminic loratadine should be considered first to personalize the clinical management of COVID-19 and selected other alarming viral infections.

COVID-19 mortality paradox (United States vs Africa): Mass vaccination vs early treatment

“…I have been fully dedicated to the clinic until mid-December 2022 when knowledge about my protocol has spread, especially after appearing in three TV shows. At that point, I decided to take a break, return to telemedicine and traditional medicine in charitable clinics to have more time to resume my academic activity and share my updated clinically gained knowledge globally[ 1 , 3 , 20 , 27 , 28 ]. Importantly, my family; especially my parents in their 80s and my young daughters were the guiding light in my quest for a safe cure, as well as to repurpose a safe old vaccine which we all received it once[ 29 ].…”

“…I repeatedly argued, with fervent decline of any opportunity for peer review, that mass vaccination campaigns, drugs like remdesivir, dexamethasone, favipiravir, molnupiravir, monoclonal antibodies as well as Paxlovid are inducing the evolution of more and more virulent immune-evasive SARS-CoV-2 variants that could prolong and worsen the global misery and division in which we live[ 3 , 12 ]. Meanwhile, I also repeatedly advocated for the use of immune-modulatory drugs such as those used in Kelleni’s and Expanded Kelleni’s protocol[ 1 , 18 , 20 , 25 , 27 ] as the right approach to treat and abort SARS-CoV-2 infection and end this pandemic. Moreover, I occasionally used Kelleni’s protocol (nitazoxanide and/or NSAIDs) in successful post-exposure prophylaxis of close contacts of SARS-CoV-2 patients.…”

“…As of October 1, 2023 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still evolving and the potential to return to square one remains valid[ 1 ]. Unfortunately, very few lessons have been learned since November 2019, if any[ 2 ] despite the fact that coronavirus disease 2019 (COVID-19) global mortality has approached seven million people, to be noted that this abstract and underestimated number[ 3 ] can never reflect the personal suffering of millions of families.…”

What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms

“…Interestingly, multiple clinical trials highlighted the role of nitazoxanide in reducing the risk of COVID-19 progression, decreasing the median time for clinical recovery, and reducing the SARS CoV-2 viral load [ 53 – 55 ]. Indeed, the nitazoxanide/azithromycin combination has been suggested as a new protocol for early management of COVID-19 [ 56 ].…”

Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach

“…Tinnitus can be a very frustrating disorder and it affects millions of people all over the world and the numbers of patients have risen sharply amid COVID-19 pandemic and Long COVID Syndrome, and though my self-report has known limitations including the risk of bias and the possibility of individual variations, yet the scientific basis that led me to try metformin as described in this manuscript, i.e., combining pathophysiology and pharmacology, was similar in its structure to the one that has led to Kelleni’s protocol and roadmap (Kelleni 2020 , 2022 , 2023a , b , c ) and likewise I tried it first on myself wishing other patients might benefit from it.…”